Localised grade 2 non-Hodgkin's lymphoma: Results of treatment with radiotherapy (BNLI report no. 24)

Lamb, D.S.; Hudson, G. Vaughan; Easterling, M.J.; MacLennan, Kenneth; Jelliffe, A.M.

doi:10.1016/s0009-9260(84)80085-9

Cited by 27 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hallahan et al (1989) reported 7/10 CR's to salvage chemotherapy but only one was durable. Most other series have reported CR salvage rates of between 20% and 50% (Monfardini et al, 1980;Kaminski et al, 1986;Armitage & Wen, 1987;Richards et al, 1989;Lamb et al, 1984 (Vokes et al, 1985;Monfardini et al, 1980;Kaminski et al, 1986;Hallahan et al, 1989;Peckham et al, 1975;Lamb et al, 1984;Kantarjian et al, 1984;Reddy et al, 1989).…”

mentioning

confidence: 97%

See 1 more Smart Citation

Involved field radiotherapy or chemotherapy in the management of stage I nodal intermediate grade non-Hodgkin's lymphoma

Jeffery

Mead²,

Whitehouse³

et al. 1991

Br J Cancer

View full text Add to dashboard Cite

Early stage intermediate grade non-Hodgkin's lymphoma (NHL) is frequently treated with chemotherapy alone or in conjunction with radiotherapy. We have managed clinical Stage I nodal, intermediate grade NHL with involved field radiotherapy alone for non-bulky (less than 5 cm post-surgery) disease or combination chemotherapy alone for more bulky disease. Forty-three patients were treated between 1978 and 1989. Of the 30 patients with non-bulky disease treated with radiotherapy, 29 (97%) achieved complete remission (CR). Thirteen (42%) patients relapsed after radiotherapy and ten of these achieved a further CR (durable in eight) following salvage chemotherapy. Eleven patients with bulky disease received combination chemotherapy with nine (82%) attaining CR (durable in eight). Two patients with bulky disease received radiotherapy-both achieved CR, but have relapsed and died of lymphoma. Overall actuarial 5 year survival for the total group is 77% with a median follow-up of 30 months (range 3-119 months). The 5 year actuarial survival for the 30 patients with non-bulky disease treated with radiotherapy is 86% at a median follow-up of 39 months (range 8-119 months). The 4 year actuarial survival of the 11 patients treated with chemotherapy is 60% with a median follow-up of 25 months (range 3-55 months). We conclude that involved field radiotherapy alone is efficacious for clinical stage I patients with non-bulky nodal intermediate grade NHL and that patients relapsing after radiotherapy are adequately salvaged by chemotherapy. Patients with bulky disease have an inferior survival and should receive combination chemotherapy.

show abstract

mentioning

confidence: 97%

“…bBone, two; tonsil, one; liver, one; skin, one. respectively (Kaminski et al, 1986;Peckham et al, 1975;Chen et al, 1979;Lamb et al, 1984;Mauch et al, 1985).…”

mentioning

confidence: 99%

Involved field radiotherapy or chemotherapy in the management of stage I nodal intermediate grade non-Hodgkin's lymphoma

Jeffery

Mead²,

Whitehouse³

et al. 1991

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Similar results have also been reported previously by Kim and Fayos12. Radiotherapy is effective local treatment for orbital non-Hodgkin's lymphoma1,4,12 and will be curative in a substantial number of patients. In a review of both nodal and extranodal grade 2 non-Hodgkin's lymphoma, Lamb et al 16 reported that local response was dependent on the radiotherapy dose and only reached 100% for doses in excess of 4500 cGy. Using a schedule of 200cGy/day such a regimen would have a time, dose and fractionation factor (TDF) of 73.…”

Section: Discussionmentioning

confidence: 99%

Primary Non-Hodgkin's Lymphoma of the Orbit

1988

View full text Add to dashboard Cite

show abstract

“…Other reports suggest higher doses >40 Gy (43) for high-grade malignant NHL, especially if the disease is bulky (4, 43). A British study found a dose-response association of 100% local control at 45 Gy o r more for high-grade malignant NHL (13).…”

Section: I12mentioning

confidence: 99%

“…One study reported 18% local recurrence if the dose was less than 40 Gy and 5% local recurrence at higher doses (49). An EORTC report noted 30% local recurrence at a dose <45 Gy and 13%1 local recurrence was observed at a dose >45 Gy (28), and a British study found loo'%, local control at a dose >45 Gy (13). Local relapse of 3%) to lo'%, was reported after radiotherapy alone (13.…”

Section: Rudiotherapymentioning

confidence: 99%

Non-Hodgkin's Lymphomas (NHL)

Gustafsson

1996

Acta Oncologica

View full text Add to dashboard Cite

Summary and ConclusionsThis synthesis of the literature on radiotherapy for non-Hodgkin's lymphomas is based on 158 scientific articles, including 16 randomized studies, 18 prospective studies, and 90 retrospective studies. These studies involve I4 137 patients.-Non-Hodgkin's lymphomas are highly radiosensitive, and local recurrence following radiotherapy is unusual.-Radiotherapy probably cures approximately ~O"/U of both low-grade and high-grade malignant NHL at stage 1. Involved field is apparently sufficient, however, higher doses are required for high-grade malignant lymphomas.

show abstract

Localised grade 2 non-Hodgkin's lymphoma: Results of treatment with radiotherapy (BNLI report no. 24)

Cited by 27 publications

References 14 publications

Involved field radiotherapy or chemotherapy in the management of stage I nodal intermediate grade non-Hodgkin's lymphoma

Involved field radiotherapy or chemotherapy in the management of stage I nodal intermediate grade non-Hodgkin's lymphoma

Primary Non-Hodgkin's Lymphoma of the Orbit

Non-Hodgkin's Lymphomas (NHL)

Contact Info

Product

Resources

About